The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.

The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.

With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.

Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).

《免疫药理学与免疫毒理学》杂志致力于针对免疫系统的临床前和临床药物发现和开发。研究涉及各种化合物（包括小分子药物和生物制剂）对免疫活性细胞和免疫反应的免疫调节作用，以及外来生物和药物产生的免疫毒性。只有描述特定化合物（而非提取物）机制的研究才是该杂志感兴趣的。

该杂志将优先考虑慢性炎症、过敏、自身免疫、癌症等疾病的免疫治疗的临床前和临床研究。小分子药物、疫苗和生物制剂对中枢免疫靶点的影响以及基于细胞的治疗，包括树突状细胞治疗、T 细胞过继转移和干细胞治疗，都是特别感兴趣的主题。我们也欢迎针对免疫系统内潜在新药靶点或免疫药理学药物开发新技术的出版物。

该期刊以免疫科学为重点，关注药物开发、免疫治疗和毒理学，涵盖感染、过敏、炎症、肿瘤免疫学、退行性疾病、免疫缺陷、神经病学、动脉粥样硬化等领域。

《免疫药理学和免疫毒理学》将接受原创手稿、简讯、评论、小型评论、评论、临床试验和临床病例，条件是报告的结果基于原创、临床或基础研究，且未以任何语言在任何期刊上发表过（以摘要形式提交给科学会议和研讨会的论文除外）。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-毒理学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为2.9，平均审稿速度为 偏慢,4-8周 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。